ACCESS360 Stroke Prevention Initiative Launched
Analysis based on 7 articles · First reported Sep 03, 2026 · Last updated Sep 04, 2026
The initiative is expected to modestly increase access to stroke prevention treatments and services in Malaysia, potentially benefiting Novartis — Sandoz's market share in affordable cardiovascular medicines. It may also enhance Alpro Pharmacy's patient engagement and Doc2Us's digital health adoption, though the financial impact is likely limited in the near term.
On September 4, 2026, Alpro Pharmacy, Novartis — Sandoz Malaysia, and Doc2Us launched ACCESS360, a collaborative initiative in Malaysia to improve stroke prevention accessibility and affordability. The program integrates Alpro's network of over 300 community pharmacies and 1,000 healthcare professionals, Novartis — Sandoz's affordable medicines, and Doc2Us's digital health platform. ACCESS360 provides patient education, pharmacist telehealth consultations, and referrals to online doctors, aiming to support stroke prevention, medication adherence, and continuity of care for at-risk individuals, survivors, and caregivers. Stroke is a leading cause of death and disability in Malaysia, with over 40,000 annual hospital admissions and a 26.4%-30% recurrent stroke rate within five years.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard